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Summary: We tested 122 biological reagents including laboratory quality assurance sera and therapeutic
human immune serum globulin products using an immunoenzymometric assay (IEMA) for HIV-1 antigens.
Biological reagents tested were 64 HIV-1 antibody non-reactive and 44 HIV-1 antibody reactive quality
assurance samples, and 14 HIV-1 antibody reactive human immune serum globulins from 21 manufacturers.
Twenty-one of these biological reagents were previously reported by us äs Western blot reactive.
All 122 samples tested were non-reactive for HIV-1 antigens. Low incidence of HIV-1 antigen in these biological
reagents should not alter laboratory safety practices in which all samples are considered infectious. Use of
HIV-1 antigen measurements, either alone or with HIV-1 antibody determinations does not increase the
likelihood of detecting HIV-1 reactive samples.
Introduction
Although the acquired inununodeficiency syndrome
(AIDS) was first reported in 1981, retrospective eval-
uation suggests that AIDS may have occurred in the
United States almost 10 yeärs earlier. In 1984, the
causative agent was identified äs a member of the
human inununodeficiency virus family, HJV-1. More
thän 46 000 individuals in the United States had de-
veloped AIDS by the end of 1987 (1), and concern
for the widespread transmission of the disease persists.
The clinical spectrum of infectiön is broad and in-
cludes an acute viral syndrome, asymptomatic carrier
state, AIDS-related cpmplex (ARG) and fulminant
AIDS complicated by either Kaposi sarcoma, tym-
phoreticular malignancies, neurologic disorders, or
opportunistic infections.
In 1985 the U.S. Food and Drag Administration
(FDA) approved the first commercial reagents for
measurement of antibodies to HIV-1 in human sera.
Since that time* all human blood donor units have
been tested and rejected for use if HIV-1 immunoen-
zymometric assay (IEMA) antibody results are posi-
tive. Specimens which are repetitively IEMA reactive
are subjected to Western blot analyses for confirma-
tion. Also since 1985, manufacturers of quality con-
trol sera have begün testing source plasma and re-
jecting HIV-1 antibody reactive sera for quality as-
surance pools. However, human products for trans-
fusion and injection, and quality assurance reagents
produced before HIV-1 antibody testing still may be
used for a number of years before expiration. In the
United States, manufacturers routinely extend prod-
uct shelf life on a yearly basis far beyond their original
expiration dates.
Recent reports have indicated occupational risk of
AIDS to health care workers and have prompted
strengthened safety programmes (2). Whereas recipi-
ents of blood products have been at risk from treat-
ment with infectious materials, laboratory workers
may have been potentially exposed to HIV-1 infected
patients, to their sera, other body fluids, or tissues.
Evidence of HIV-1 infectiön requires identification of
specific serum IgG antibodies or Isolation of virus
from circulating peripheral blood lymphocytes,
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monocytes, or macrophages. Recent reports have in-
dicated a high incidence of HIV-1 antibodies in human
serum-based quality assurance reagents and immune
globulin preparations (3-7), although no reports of
individuals infected from these products have ap-
peared.
In contrast, whole blood packed red cells, factor VIII,
and cryo-preserved serum are among the products
reported to frequently cause AIDS when transferred
to non-infected humans. Procedures based on iden-
tification of HIV-1 antibodies have been subject to
interferences including non-specific antibodies to the
H-9 cell line from which viral antigens used in various
assays were obtained (8), heating n n-reactive sera
(9—11), and passive transfer of HIV-1 antibodies fol-
lowing treatment with human immune globulins (12).
Viral Isolation is time-consuming, expensive, and can-
not be used for large numbers of specimens. Recently
circulating HIV-1 antigen was detected in sera of in-
fected individuals who developed specific HIV-1 an-
tibodies (13), This antigen has also been found later
during the course of infection in homosexuals, hae-
mophiliacs, children born to sera positive mothers,
and in high frequency in sera of individuals with
AIDS.
The purpose of the present study was to investigate
the prevalence of HIV-1 antigens in quality assurance
sera and immune serum globulin preparations classi-
fied s HIV-1 antibody reactive and non-reactive. We
also wanted to determine whether HIV-1 antigen test-
ing might be used alone or with HIV-1 antibody testing
to increase the likelihood of identifying HIV-1 reactive
sera.
Materials and Methods
Previously we tested and classified HIV-1 antibody reactivity of
quality assurance samples and human immune globulin prep-
arations using the HTLV-III (HIV-l) IEMA test kit produced
by Abbott Laboratories, North Chicago IL, 60064, U. S. A. (3,
5). We substantiated antibody reactivity of some samples by a
second IEMA and Western blot analysis and subsequently
tested 15 additional quality assurance samples by the same
Abbott technique.
We then tested all human immune serum preparations and
quality assurance samples with the Abbott HIV-1 Ag IEMA
test kit which uses polystyrene beads coated with human anti-
body to HIV-1. A 200 μΐ sample or control was pipetted into
wells of a reaction tray and then incubated with antibody coated
beads. After incubation for 16-20 h at room temperature,
excess sample was aspirated and the beads were washed. Next,
200 μΐ of rabbit antibody to HIV-1 was added and incubated
at 4 °C for 4 h. Excess material was aspirated and beads were
washed s before. Following addition of 200 μΐ of goat anti-
rabbit IgG conjugated to horseradish peroxidase and incuba-
tion at 4 °C for 2 h, the unbound material again was aspirated
and the beads were washed. On addition of 300 μΐ of an
orthophenylenediamine solution with hydrogen peroxide, the
beads were incubated for 30 min at room temperature, and
l ml of 0.5 mol/1 sulphuric acid was added and the colour
intensity read at 492 nm using a Quantum II analyser (Abbott
Laboratories). A sample was called reactive if its absorbance
(A) was greater than, or equal to 0.05 plus the mean A of three
negative antigen controls.
We tested quality assurance reagents from the following sources:
American Dade, Miami, FL 33152;
American Monitor Corp., Indianapolis, IN 46268;
Beckman Instruments, Inc., Brea, CA 92621;
Behring Diagnostics, La Jolla, CA 92030;
Boehringer Mannheim Diagnostics, Inc., Indianapolis,
IN 46250;
Βίο-Rad Laboratories, Richmond, CA 94802;
Clinical Chemistry Consultants, femple City, CA 91780;
Fisher Scientific, Orangeburg, NY 10962;
Gamma Biologicals Inc., Houston, TX 77072;
Gilford Instrument Laboratories Inc., Irvine, CA 92714;
NMS Pharmaceuticals Inc., Newport Beach, CA 92663;
Ortho Diagnostic Systems, Raritan, NJ 08869;
Technicon Instruments Corp., Tarrytown, ΝΫ 10591.
We also tested in-house creatine kinase and cyclosporin quality
control pools, derived from discarded serum from patients in
our coronary care and transplant units.
Proficiency testing sera were obtained from the American As-
sociation for Clinical Chemistry, Washington, DC 20006; the
American Society of Clinical Pathologists, Inc., Chicago, IL
60612; the College of American Pathologists, Skpkie, IL 60077-
1034; and the South Carolina Department of Health, Columbia,
SC 29202. These commercial quality assurance reagent pools
require up to 2000 dpnor units.
Fifteen human serum globulin preparations were tested. HBIG
was from Abbott Laboratories, North Chicago, IL 80064; Hy-
perhep, Gamastan, Gamimune, HypRho-D and Hyper-Tet
were from Cutter Biological, Emeryville, CA 94608; RhoGam
was from Ortho Diagnostic Systems, Inc., Raritan, NJ 08869;
and hyper immune globulin against Varicella-Zoster was from
the American Red Cross, Washington, DC 20006.
Results
Table l lists 18 human-serum-based non-proficiency
samples, 36 human serum-Jbased proficiency samples
and 1l bovine-serum^based non-proficiency samples
which were non-reactive for HIV antibody s meas-
ured by the Abbott IEMA. Samples produced by
Beckman and Clinical Chemistry Consultants were in
a liquid matrix whereas all others were human lyoph-
ilized products. All 64 samples were non-reactive for
HIV-1 antigens.
Listed in table 2 are 24 n n-proficiency samples and
20 proficiency samples which were HIV-1 antibody
positive. The products listed are human-serum-based
except those produced by Beckman. Fourteen had·
been tested for Western blot reactivity and eight found
reactive for at least p24. The 44 specimens were found
non-reactive for HIV-1 antigens.
Shown in table 3 are 14 human immune serum glob-
ulin preparations reactive for HIV-1 antibody by the
AbbotMEMA. Three were Western blot positive (p24
and gp41), and eleven indeterminate (at least p24, p31
and p55), except for the Varicella-Zoster preparation
(p55). The 14 human immune serum globulin prepa-
rations were negative for HIV-1 .antigens.
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Tab. 1. HIV-1
Manufac-
turcr/
distributor
Antibody-ncgative samples.
Usc Lot Manufac-
turcr/
distributor
Usc Lot
Human-serum-hased non-proficiency samples
Amcr. Mon.
Dadc
Beckman
Beckman
Bio-Rad
Bio-Rad
Bio-Rad
BMC
Dade
General clinical chemistry
TDM
General clinical chemistry
General clinical chemistry
TDM
TDM
TDM
General clinical chemistry
TDM
SH1035B
TDM3-315
C403153
C404172
11301
11302
11303
3-370
TDM1-115
Dade
Dade
Dade
Fisher
Fisher
Gamma
NMS
NMS
NMS
TDM
TDM
General clinical chemistry
General clinical chemistry
General clinical chemistry
Serology
TDM
TDM
TDM
TDM2-215
TDM2-315
XLS-36A
483-014
482-014
KSL06E
R06L-3A
R07M-3A
R08H-6A
Hwnan-serum-based proficiency samples
AACC
AACC
ASCP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
TDM
TDM
General clinical chemistry
General clinical chemistry
General clinical chemislry
General clinical chemistry
Electrophoresis
Electrophoresis
Electrophoresis
Electrophoresis
Electrophoresis
Serology
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
Syphilis serology
General clinical chemistry
March (1985)
April (1985)
Lyphocheck
CP86
C-l (1985)
C-2 (1985)
C-3 (1985)
S-6 (1985)
EC-2 (1985)
EC-5 (1985)
EC-6 (1985)
EC-12(1985)
S-21 (1985)
C-4 (1985)
C-5 (1985)
C-6 (1985)
C-24 (1985)
G-6 (1985)
G-7 (1985)
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
Syphilis serology
Syphilis serology
Viral markers
Viral markers
Viral markers
Viral markers
Viral markers
Viral markers
Viral markers
Viral markers
General ciinical chemistry
General clinical chemistry
General clinical chemistry
Comprehensive
Ligand
Ligand
Ligand
G-8 (1985)
G-10 (1985)
W-12(1985)
W-13 (1985)
W-15 (1985)
W-16 (1985)
W-17(1985)
W-18 (1985)
W-19 (1985)
W-20 (1985)
C-l (1986)
C-2 (1986)
C-5 (1986)
C-2 (1987)
K-l (1987)
K-3 (1987)
Bovine-serum-based non-proßciency samples
CCC
CCC
CCC
CCC
CCC
Enzyme
Enzyme
Acid phosphatase
Carotene
Ammonia
1-15-85
334A-84
Acid Phos. 17
Carotene 9
Hi NH3 16
Dade
Dade
Dade
Dade
Technicon
Technicon
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
BSC2-203Z
BSC1-103Z
BSC1-103
BSC2-203
B4F351H
BaF361K
Non-standard abbreviations:
BMC — Boehringer Mannheim Diagnostics Inc.
CCC — Clinical Chemistry Consultants
AACC — American Association for Clinical Chemistry
ASCP — American Society of Clinical Pathologists
CAP — College of American Pathologists
TDM — Therapeutic drug monitoring
Liquid, ethylene giycol-based samples: Beckman and CCC
Discussion
Shortly after infectiön with HIV-1, viral antigens ap-
pear transiently in human sera followed by antibodies
to viral envelope structural glycoprotein (gp41) and
then the core structural proteins p!5, p!8, p24 and
p55 (13). The disappearance of detectable HIV-1 an-
tigen from the eirculation is related to development
of antibody to the core protein, p24. At this time
infected individuals are asymptomatic carriers. The
recurrence or persistence of viral antigen is associated
with disappearance of antibody to p24 and correlates
with clinical deterioration and progression to "ful-
minant" AIDS (15). Use of HIV-1 Ag testing still does
not identify individuals during the first few weeks of
acute viral infectiön (l 3).
Procedures for testing blood products and biological
reagents for clinical laboratories have required testing
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Tab. 2. HIV-1 Antibody-positive samples.
Manufaclurer/
distributor
Non-proficiency samples
Beckman
Beckman
Beckman
Beckman
Beckman
Behring
BMC
BMC
BMC
Dade
Dade
Dade
Dade
Dade
Dade
Fisher
Fisher
Gilford
Gilford
In-house
In-house
Ortho
Ortho
Technicon
Proficieucy samples
AACC
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
CAP
SCSS
SCSS
SCSS
SCSS
SCSS
SCSS
SCSS
SCSS
SCSS
SCSS
Use
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General ctinical chemistry
Protein chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
General clinical chemistry
Enzyme control
Enzyme Control
General clinical chemistry
General clinical chemistry
General clinical chemistry
TDM
Electrophoresis
Comparative clinical chemistry
Comparative clinical chemistry
Comparative clinical chemistry
Viral markers
Viral markers
General clinical chemistry
General clinical chernistry
General clinical chemistry
Syphilis serology
Syphilis serology
Syphilis serology
Syphilis serology
Syphilis serology
Syphilis serology
Syphylis serology
Syphilis serology
Syphilis serology
Syphilis serology
Lot
C407023
C407276
C407024
C407277
C407025a
011225
308
1-588
1-523
TC1-116
TC2-216
TC3-316
XSD1-124
XSD2-223
XPS-123
068^054*
069-054a
025501 b
020501 b
85-3Ca
CK High IIa
08350l3
084501b
B4F351D
TDM July 1985a
ECS 1985
K-l (1985)
K-2 (1985)b
K,3 (1985)b
W-ll (1985)
W-14 (1985)a
C2 (1986)
C3 (1986)
C4 (1986)
41 - 85a
12-86
13 - 86
14 - 86
15 - 86
16 - 86
17 - 86
18 - 86
19 - 86
20 - 86
Expiration date
Dec 1985
Jan 1986
• ' Dec 1985
Jan 1986
Dec 1985
Jan 1987
Feb 1987
Mär 1986
Mär 1986
Dec 1986
Dec 1986
Dec 1986
Mär 1988
Mär 1988
Mär 1988
Dee 1986
-r-
e-
Jan 1987
Jan 1987
Jan 1988
Jan 1988
Jan 1987
- - ·
Non-standard abbreviations:
SCSS — South Carolina Syphilis Survey
TDM - Therapeutic drug monitoring
a
 — Western blot positive
b
 — Western blot negative
of donor sera for antibody to HIV-1 since 1985. Use
of antigen testing may be of value in the identification
of individuals who have been infected with HIV-1 and
who have not yet developed an antibody response.
Detection of HIV-1 antigen may also prove useful in
monitoring patients for disease progression.
The Abbott HIV-1 Ag assay uses human polyclonal
antibody reagent to viral core antigen p24 and enve-
lope antigen gp41. Assay analytical sensitivity is ap-
proximately 30 to 40 ng/1 for p24 and 200 to 300 ng/1
for gp41. Average HIV-1 Ag values in AIDS patients
are approximately 100 to 500 ng/1 with levels äs high
äs 30 g/l in some patients (14).
Our previoüs studies indicate that the prevalence of
HIV-1 antibodies in quality assurance sera or huinan
immune globulin reagents was 31 and 100%, respec-
tively (3, 5), and approximates to the seropositivity
in high risk groups.
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Tab. 3. HIV-1 Anlibody-positive human immune serum glob-
ulin preparations.
Sample
Hyperhep
Hyperhep
Gamastan
Gamastan
Gamastan
Gamastan
Gamastan
Gamimune
Gamimune
Hyper-Tet
HypRho-D
H-BIG
RhoGam
Varicella-Zoster
Immune
globulin for:
Hepatitis
Hepatitis
Hepatitis
Hepatitis
Hepatitis
Hepatitis
Hepatitis
Hepatitis
Hepatitis
Tetanus
Rh
Hepatitis
Rh
—
Lot
(Cutter 16A06BB)
(Cutter 160A04AC)
(Cutter 15BO1B)
(Cutter 15N05B)
(Cutter 15N07A)
(Cutter NF004M)
(Cutter 15P02B)
(Cutter 45 Nil)
(Cutter 45N1 6)
(Cutter 14A05B)
(Cutter 21A06A)
(Abbott H1O1OOA)
(Ortho RHC600)
(Red Cross MVZIG-21)
The highest reported prevalence of HIV-1 antibodies
in high risk groups of haemophiliacs, intravenous
drug users and homosexuals was 74, 59 and 36%,
respectively (l 5). For that reason, it is surprising that
none of the 122 human-based samples tested was
reactive for HIV-1 antigen. Some of the 53 quality
assurance samples which were non-reactive for HIV-
1 antibody may represent situations in which patients
were antibody negative and if tested for antigen,
would be reactive, thereby indicating an acute infec-
tion. However, no samples reactive only for HIV-1 Ag
were found. This finding is similar to reports of
screening of sera from 1000 blood donors for HIV-1
antigen reactivity and identifying no HIV-1 antigen-
positive, antibody-negative sera (7).
Although 44 quality assurance samples and 15 intra-
venous globulin preparations were reactive for HIV-
1 antibodies, none was reactive for HIV-1 antigen.
Three of the quality assurance samples and 14 human
immune globulin reagents previously had been tested
and found to be Western blot positive (presence of
p24 and gp41). Recently, widely accepted criteria for
Western blot positivity have been developed, and they
include reactivity for any two of the following viral
proteins: p24, gp41 and gpl20/gpl60 (16). This lack
of antigen reactivity may indicate that sera for these
reagents was obtained from donors during the carrier
state when HIV-1 antigen is absent and antibodies are
pfesent. These findings are analogous to the report
that when the HIV-1 antibody-reactive sera from 13
homosexual men supposedly in the carrier state were
tested for HIV-1 antigen, only one showed antigen-
aemia (17).
When serum specirnens from individuals with fulmi-
nant AIDS are tested by Western blot technique they
routinely have the gp41 antibody without the p24
antibody (15). However, 21 Western blot results of
biological reagents previously reported by us had p24
reactivity without gp41 reactivity. When Western blot
reactivity was studied using sera from a large group
of patients with AIDS or at a high risk for AIDS,
approximately 40% had gp41 bands only (18). The
sera used for our studies may have been obtained
from a group of patients whose disease had not pro-
gressed to "fulminant'* AIDS, but were asymptomatic
carriers. It has been reported that individuals who are
identified in high risk groups for AIDS voluntarily
refrain from blood donation (18). A similar voluntary
deferral may also occur in those individuals who are
donors of sera for quality assurance reagents. Alter-
natively these individuals may be too ill with fulmi-
nant AIDS to consider sera donation. Because labo-
ratory quality assurance reagents represent sera
pooled from up to 2000 donors, another potential
reason for antigen non-reactivity may be reaction of
an antigen reactive unit with an antibody reactive unit
thereby rendering antigen non-detectable.
The inability to culture HIV-1 from quality assurance
reagents and lack of substantiated infectivity of hu-
man immune globulins support our findings that an-
tigen was not detected in products tested (20). Recent
reports have presented evidence that heating non-
reactive specimens causes false positive results
(9 — 11), and sample treatment and handling by man-
ufacturers of quality assurance reagents might have
been responsible for similar results. In the survey by
the College of American Pathologists (CAP) false
positive results for HIV-1 antibody tests were noted
when quality assurance specimens were tested with
reagents from one manufacturer (2). Although we
used the same source of reagents for HIV-1 antibody
testing, it is doubtful that our antibody results re-
present false positive reactivity. We validated HIV-1
antibody assay results by demonstrating parallelism
between positive samples tested and sera from patients
with AIDS, verified some results with a second IEMA
and Western blot procedures, and found appropriate
controls non-reactive. Although haemophiliacs have
developed AIDS after treatment with Factor VIII,
the human immune globulins we tested had been
subjected to Cohn fractionation, and it is possible that
viral antigen present in these preparations may have
been removed by this process.
Since our report that quality assurance sera contained
HIV-1 antibodieSj manufacturers of these reagents
have begun testing donors, and excluding those do-
nors who demonstrate sera reactivity for HIV-1 anti-
body. Sera used by the South Carolina Syphilis Survey
Programme has continued to react positively for HIV-
1 antibody in our hands. However, correspondence
with the Organizers of this Programme indicates that
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this sera has been Ireated for 30 min at 56 °C to
inactivate live virus, and it is known thal heating sera
causes false positive HIV-1 antibody results. Heating
of sera does not alter HIV-1 Ag reactivity (22).
We postulate that sera from individuals with AIDS
obtained for quality assurance reagents or human
immune serum globulin preparations were obtained
when donors were asymptomatic, and that HIV-1
antigen may have been removed frorri human immune
serum globulins preparations during Cohn fractiona-
tion. Our findings that biological reagents tested in
this study do not contain HIV-1 antigen support other
evidence that quality assurance reagents and human
immune serum globulins do not contain viable Virus.
This should not deter clinical labo/ratories from safety
practices in which all samples are considered infec-
tious.
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